-

UVCeed to Showcase Award-Winning Disinfection Device at CES 2024

Company to unveil new app capabilities to further enhance and improve disinfection process

EFFINGHAM, Ill.--(BUSINESS WIRE)--UVCeed today announced it will showcase its flagship disinfection device at CES 2024 in Las Vegas, Nevada. The award-winning UVCeed is the only consumer smart mobile UV-C disinfection device that guides a user from start to finish to ensure 99.99 percent effectiveness in killing germs, bacteria and viruses. UVCeed will hold live demonstrations and unveil new device accessories and capabilities in booth 8372, North Hall, in the Las Vegas Convention Center. CES 2024 takes place January 9-12, 2024.

“UVCeed has emerged as a key ally to help protect families and individuals from exposure to harmful pathogens,” said Justin Beyers, co-inventor and engineer, UVCeed. “We’re excited to return to CES where we’ll be announcing exciting enhancements to the UVCeed app to enable easier ways to disinfect a wider breadth of objects and surfaces.”

UVCeed, now available for both iOS and Android, is the only disinfecting device that utilizes the processing power of a user’s smartphone. Outfitted with powerful mercury-free LED UV light rays and multiple sensors, proprietary iCide smart dosage and iCide safety technology, UVCeed is safe and easy to use anytime and anywhere. To see how UVCeed works, watch this video.

UVCeed has won numerous industry awards for its innovation, most recently earning a Fast Company 2023 Next Big Things in Tech Award in the Wellness and Fitness category. UVCeed has also received a TMC 2023 Pandemic Tech Innovation Award, and a 2022 Mom’s Choice Award honoring excellence in family-friendly media, products and services.

For sales and distribution inquiries, contact Eileen Murphy at sales@uvceed.com.

About UVCeed

UVCeed is the first personal AI-powered mobile UVC disinfectant platform for work, home, school, or travel. It is designed by Bonutti Research, a medical device incubator with a 30+ year history of innovation, over 400 patents and applications, and 700 licenses. As a practicing surgeon, Dr. Peter Bonutti understands the importance of infection control and developed UVCeed to create a convenient device for personal use that is safe and effective. UVCeed’s patented technology leverages machine learning and computer vision to ensure safe usages and proper amount of energy is used to achieve the desired level of disinfection. For more information, visit https: www.uvceed.com.

Contacts

UVCeed Contact
Donna Loughlin Michaels
408.393.5575
donna@lmgpr.com

UVCeed


Release Versions

Contacts

UVCeed Contact
Donna Loughlin Michaels
408.393.5575
donna@lmgpr.com

Social Media Profiles
More News From UVCeed

Smart UVCeed Disinfection Device & Disinfection Lid Bundle Makes it Easier to be "GERMFREE" Just in Time for Spring

EFFINGHAM, Ill.--(BUSINESS WIRE)--UVCeed the only UV-C smart device effective at killing germs, bacteria and viruses, announced today a limited time offer to purchase it’s multi-award winning smart UVC disinfection device and disinfection lid for cleaning thermal cups at 50% off retail price with the code GERMFREE. Designed to kill up to 99.99% of germs, bacteria, and viruses including highly contagious Norovirus, a leading cause of foodborne illness. UVCeed has received multiple awards for its...

UVCeed Wins Fast Company 2023 Next Big Things in Tech Award

EFFINGHAM, Ill.--(BUSINESS WIRE)--UVCeed today announced it has won a Fast Company 2023 Next Big Things in Tech Award. The company was honored in the Wellness and Fitness category for its flagship product, the first personal AI-powered mobile UV-C disinfectant platform. Fast Company’s Next Big Things In Tech Awards highlight new technology breakthroughs from around the world that will help define the future of the industries they serve. “With new COVID cases on the rise, kids back in school, an...

Realeve Unveils Breakthrough Solution to Treat Central Nervous System Disorders Including Stroke and Cluster Headache; Bypasses Brain’s Natural Barrier to Deliver Therapeutics

EFFINGHAM, Ill.--(BUSINESS WIRE)--Realeve today announced it has received a multimillion dollar grant to support a study at Cleveland Clinic aimed at revolutionizing post-stroke recovery. The planned study will use Realeve’s Pulsante® micro-neuromodulation system, the first externally powered implantable neuromodulation device which stimulates the sphenopalatine ganglion (SPG), in conjunction with hyperbaric oxygen to potentially enhance blood circulation in stroke patients, minimizing brain da...
Back to Newsroom